NCT02478892
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
Recruiting · Not specified · Abramson Cancer Center at Penn Medicine · registry updated 2026-02-05
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.
Inclusion
- Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation
- If no history of PDAC in a first or second degree relative, age \>= 50
- If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer